Denali Therapeutics Inc.·4

Jan 11, 5:28 PM ET

Watts Ryan J. 4

4 · Denali Therapeutics Inc. · Filed Jan 11, 2024

Insider Transaction Report

Form 4
Period: 2024-01-09
Watts Ryan J.
DirectorPresident and CEO
Transactions
  • Sale

    Common Stock

    2024-01-09$19.78/sh7,818$154,6402,268,363 total(indirect: See footnote)
Holdings
  • Common Stock

    221,897
Footnotes (4)
  • [F1]Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
  • [F2]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.60 to $20.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  • [F3]The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
  • [F4]Includes 221,897 RSUs.

Documents

1 file
  • 4
    wk-form4_1705012085.xmlPrimary

    FORM 4